Screener
Opus Genetics IRD Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$8.1M-9.1% | -$65.54M-700% | -$16.52M+53.0% | -$17.45M-132% | -$7.42M+4.4% | ||
| $14K0.0% | $13K0.0% | $13K+30.0% | $13K— | $14K— | ||
| $1.41M+57.0% | $1.46M+60.4% | $774K-2.6% | $816K+5.2% | $896K+11.2% | ||
| -$11.95M-16.4% | -$12.73M-41.5% | -$9.83M-32.2% | -$6.16M-20.0% | -$10.27M-40.8% | ||
| —— | —— | $0-100% | $0-100% | $0-100% | ||
| $0— | $0— | $0-100% | $0— | $0— | ||
| $40.9M+4,415% | $27.6M+34.8% | $24.11M— | $4.54M+1,187% | $906K-41.2% | ||
| $28.95M— | $14.87M+29.6% | $14.28M+326% | —— | —— |
FAQ
- How much cash does Opus Genetics generate?
- Opus Genetics (IRD) generated -$40.7M in operating cash flow over the trailing twelve months.
- Where does Opus Genetics's cash flow data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
